Daniel Heng, MD

Articles by Daniel Heng, MD

Daniel Heng, MD, on How Belzutifan/Lenvatinib Fills an Unmet Need After Immunotherapy in RCC

October 5th 2026

Daniel Heng, MD, discusses the FDA approval of belzutifan plus lenvatinib in RCC, managing hypoxia and anemia, and how it may affect treatment sequencing.

Latest Updated Articles

Trending on Targeted Oncology - Immunotherapy, Biomarkers, and Cancer Pathways

Behind the FDA Approval: Rusfertide Redefines the Polycythemia Vera Paradigm

Ubamatamab Shows Durable Responses in Low-Grade Serous Ovarian Cancer

FDA Grants Fast Track Designation to TRE-515 for KRAS G12C NSCLC

Pirtobrutinib Gains FDA Approval for Frontline CLL/SLL in Select Patients

Extended Survival Raises New Questions on Imaging and Treatment Intensification in ROS1+ NSCLC